A Phase 1 interventional study of Enlicitide decanoate in Healthy, sponsored by Merck Sharp & Dohme LLC. Completed at 1 site in United States. Open to participants aged 19 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-11-18.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to learn what happens to the amount of enlicitide decanoate in the blood when enlicitide decanoate is given in different formulations.
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive a single dose of enlicitide decanoate formulation 1 on Day 1 on an empty stomach.
Drug: Enlicitide decanoate
Participants will receive a single dose of enlicitide decanoate formulation 2 on Day 1 on an empty stomach.
Drug: Enlicitide decanoate
Oral tablet
Also known as: MK-0616
Area Under the Concentration-Time Curve from 0 to 24 hours (AUC0-24) of enlicitide decanoate
Blood samples will be collected to determine the AUC0-24 of enlicitide decanoate.
Time frame: Predose and at designated timepoints (up to 24 hours postdose)
Area Under the Concentration-Time Curve from 0 to Time of Last Quantifiable Sample (AUC0-last) of enlicitide decanoate
Blood samples will be collected to determine the AUC0-last of enlicitide decanoate.
Time frame: Predose and at designated timepoints (up to 168 hours postdose)
Area Under the Concentration-Time Curve from 0 to Infinity (AUC0-inf) of enlicitide decanoate
Blood samples will be collected to determine the AUC0-inf of enlicitide decanoate.
Time frame: Predose and at designated timepoints (up to 168 hours postdose)
Maximum Plasma Concentration (Cmax) of enlicitide decanoate
Blood samples will be collected to determine the Cmax of enlicitide decanoate.
Time frame: Predose and at designated timepoints (up to 168 hours postdose)
Time to Maximum Plasma Concentration (Tmax) of enlicitide decanoate
Blood samples will be collected to determine the Tmax of enlicitide decanoate.
Time frame: Predose and at designated timepoints (up to 168 hours postdose)
Apparent Terminal Half-Life (t1/2) of enlicitide decanoate
Blood samples will be collected to determine the t1/2 of enlicitide decanoate.
Time frame: Predose and at designated timepoints (up to 168 hours postdose)
Apparent Clearance (CL/F) of enlicitide decanoate
Blood samples will be collected to determine the CL/F of enlicitide decanoate.
Time frame: Predose and at designated timepoints (up to 168 hours postdose)
Apparent Volume of Distribution During Terminal Phase (Vz/F) of enlicitide decanoate
Blood samples will be collected to determine the Vz/F of enlicitide decanoate.
Time frame: Predose and at designated timepoints (up to 168 hours postdose)
Number of Participants Who Experience an Adverse Event (AE)
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of the study intervention, whether or not considered related to the study intervention.
Time frame: Up to approximately 44 days
Number of Participants Who Discontinue Study Treatment Due to an AE
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of the study intervention, whether or not considered related to the study intervention.
Time frame: Up to approximately 44 days
Plan to share: Yes — http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf
Data sharing details ↗ · engagezone.msd.com
Ran from Mar 2024 to primary completion in May 2024, 1 month.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: MK-0616